• Our Team
  • Mucosal Vaccines
  • Showcase
  • News
    • Investors
    • Aptimmune Biologics Adds CEO and Technical Consultant to Management Team
    • Aptimmune Biologics and Kemin Industries Announce Partnership
    • Aptimmune Completes Series B Funding, Moves to St. Louis
    • Aptimmune Receives Iowa Biotech’s Top Company Award
    • ISU and Aptimmune Improve PRRSV Isolation
    • Aptimmune Selected by Yield Lab for Ag Tech Accelerator Program
    • Aptimmune Biologics Raises $2.75 Million
    • Novel Technology to Fight Swine Pathogens
    • Aptimmune Offering New Vaccination Technology
    • Swine Vaccine Maker at Ag Innovations Showcase
  • Join Our Team
  • Contact
  • Our Team
  • Mucosal Vaccines
  • Showcase
  • News
    • Investors
    • Aptimmune Biologics Adds CEO and Technical Consultant to Management Team
    • Aptimmune Biologics and Kemin Industries Announce Partnership
    • Aptimmune Completes Series B Funding, Moves to St. Louis
    • Aptimmune Receives Iowa Biotech’s Top Company Award
    • ISU and Aptimmune Improve PRRSV Isolation
    • Aptimmune Selected by Yield Lab for Ag Tech Accelerator Program
    • Aptimmune Biologics Raises $2.75 Million
    • Novel Technology to Fight Swine Pathogens
    • Aptimmune Offering New Vaccination Technology
    • Swine Vaccine Maker at Ag Innovations Showcase
  • Join Our Team
  • Contact

The Future of Disease Protection is Now

Aptimmune Biologics has created a series of advanced enabling technologies which provide solutions to today's most challenging and economically important swine diseases. Using the BarricadeR platform technology, we have empowered stakeholders to address the Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and Swine Influenza A virus (IAV-S) vaccine markets in multiple geographies. Additionally, our R&D is focused in creating vaccines against the highly contagious African Swine Fever virus (ASFV) for regions devastated by this disease.

Aptimmune's Technology

Our Team

Investment Opportunities

Want to know more?

Contact us.

© 2025 Aptimmune